Home › Companies › Trevi Therapeutics, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Trevi Therapeutics, Inc.’s Form 8-K, filed June 17, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2025: 5 items on Trevi Therapeutics, Inc.’s Form 8-K, filed June 17, 2025: 2 elected · 3 approved.
Significant dissent: 1 director (20.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Trevi Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Trevi Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jennifer Good | 78,827,140 | -- | -- | 268,129 | 9,892,671 | 99.7% | Elected | — |
| Elect Director: Anne VanLent | 62,868,529 | -- | -- | 16,226,740 | 9,892,671 | 79% | Elected | — |
| 2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 | 88,898,357 | 56,824 | 32,759 | -- | -- | 99.9% | Approved | — |
| 3. Compensation of the Company's named executive officers | 78,346,572 | 722,449 | 26,248 | -- | 9,892,671 | 99.1% | Approved | — |
| 5. Amendment to the 2019 Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments | 78,703,357 | 370,380 | 21,532 | -- | 9,892,671 | 99.5% | Approved | — |
Source: Trevi Therapeutics, Inc., Form 8-K, filed with the SEC on June 17, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
133 asset managers disclosed a vote on at least one Trevi Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Trevi Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders: Anne VanLent
Trevi Therapeutics, Inc.’s own tally for this item (“Elect Director: Anne VanLent”): 62,868,529 for, 16,226,740 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to the Board as Class III directors for terms expiring at the 2028 annual meeting of stockholders.”
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 40 asset managers below reported 6,559,311 for, 3,480,373 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,014,667 | 0 | 0 | 0 | For |
| BlackRock | 525,826 | 0 | 0 | 2,365,128 | Mixed |
| Fidelity | 1,495,735 | 0 | 0 | 0 | For |
| TIAA | 265,706 | 0 | 0 | 0 | For |
| Charles Schwab | 211,923 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 152,415 | Withhold |
| SEI | 0 | 0 | 0 | 145,268 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 126,779 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 92,659 | Withhold |
| American Century | 0 | 0 | 0 | 76,904 | Withhold |
| Global X | 0 | 0 | 0 | 43,327 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 42,881 | Withhold |
| Invesco | 0 | 0 | 0 | 41,493 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 38,062 | Withhold |
| Northern Trust | 0 | 0 | 0 | 35,216 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 32,950 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 30,274 | Withhold |
| Pacific Life | 0 | 0 | 0 | 27,935 | Withhold |
| Brighthouse | 0 | 0 | 0 | 26,829 | Withhold |
| State Street | 0 | 0 | 0 | 25,212 | Withhold |
| John Hancock | 0 | 0 | 0 | 24,718 | Withhold |
| AQR | 0 | 0 | 0 | 23,960 | Withhold |
| Bridge Builder Trust | 0 | 0 | 0 | 21,872 | Withhold |
| Voya | 0 | 0 | 0 | 19,830 | Withhold |
| ProShares | 0 | 0 | 0 | 18,485 | Withhold |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders: Jennifer Good
Trevi Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer Good”): 78,827,140 for, 268,129 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to the Board as Class III directors for terms expiring at the 2028 annual meeting of stockholders.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 40 asset managers below reported 9,975,534 for, 64,150 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,014,667 | 0 | 0 | 0 | For |
| BlackRock | 2,890,954 | 0 | 0 | 0 | For |
| Fidelity | 1,495,735 | 0 | 0 | 0 | For |
| TIAA | 265,706 | 0 | 0 | 0 | For |
| Charles Schwab | 211,923 | 0 | 0 | 0 | For |
| Equitable | 152,415 | 0 | 0 | 0 | For |
| SEI | 145,268 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,779 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,659 | 0 | 0 | 0 | For |
| American Century | 76,904 | 0 | 0 | 0 | For |
| Global X | 43,327 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 42,881 | 0 | 0 | 0 | For |
| Invesco | 41,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 38,062 | 0 | 0 | 0 | For |
| Northern Trust | 35,216 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 32,950 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 30,274 | Withhold |
| Pacific Life | 27,935 | 0 | 0 | 0 | For |
| Brighthouse | 26,829 | 0 | 0 | 0 | For |
| State Street | 25,212 | 0 | 0 | 0 | For |
| John Hancock | 24,718 | 0 | 0 | 0 | For |
| AQR | 23,960 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,872 | 0 | 0 | 0 | For |
| Voya | 19,830 | 0 | 0 | 0 | For |
| ProShares | 18,485 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.5% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE TREVI THERAPEUTICS, INC. 2019 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE PLAN BY 6,000,000 SHARES OF COMMON STOCK, AND MAKE CERTAIN OTHER AMENDMENTS.
Trevi Therapeutics, Inc.’s own tally for this item (“5. Amendment to the 2019 Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments”): 78,703,357 for, 370,380 against — passed, per its Form 8-K filed June 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The amendment to the 2019 Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments, was approved.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,014,667 | 0 | 0 | 0 | For |
| BlackRock | 2,890,954 | 0 | 0 | 0 | For |
| Fidelity | 1,495,735 | 0 | 0 | 0 | For |
| TIAA | 265,706 | 0 | 0 | 0 | For |
| Charles Schwab | 211,923 | 0 | 0 | 0 | For |
| Equitable | 152,415 | 0 | 0 | 0 | For |
| SEI | 145,268 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,779 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,659 | 0 | 0 | 0 | For |
| American Century | 0 | 76,904 | 0 | 0 | Against |
| Global X | 43,327 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 42,881 | 0 | 0 | 0 | For |
| Invesco | 41,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 38,062 | 0 | 0 | 0 | For |
| Northern Trust | 35,216 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 32,950 | 0 | 0 | 0 | For |
| Dimensional | 30,274 | 0 | 0 | 0 | For |
| Pacific Life | 27,935 | 0 | 0 | 0 | For |
| Brighthouse | 26,829 | 0 | 0 | 0 | For |
| State Street | 25,212 | 0 | 0 | 0 | For |
| John Hancock | 24,718 | 0 | 0 | 0 | For |
| AQR | 23,960 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,872 | 0 | 0 | 0 | For |
| Voya | 19,830 | 0 | 0 | 0 | For |
| ProShares | 18,485 | 0 | 0 | 0 | For |
Fund voting reports, all 40 managers: 9,938,329 for, 83,236 against, 18,119 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9,434,612 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 9,434,612 for.
Combines 5 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
Trevi Therapeutics, Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 78,346,572 for, 722,449 against — passed, per its Form 8-K filed June 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers was approved, on an advisory basis.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,014,667 | 0 | 0 | 0 | For |
| BlackRock | 2,890,954 | 0 | 0 | 0 | For |
| Fidelity | 1,495,735 | 0 | 0 | 0 | For |
| TIAA | 265,706 | 0 | 0 | 0 | For |
| Charles Schwab | 211,923 | 0 | 0 | 0 | For |
| Equitable | 152,415 | 0 | 0 | 0 | For |
| SEI | 145,268 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,779 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,659 | 0 | 0 | 0 | For |
| American Century | 0 | 76,904 | 0 | 0 | Against |
| Global X | 43,327 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 42,881 | 0 | 0 | Against |
| Invesco | 0 | 41,493 | 0 | 0 | Against |
| AIG/SunAmerica | 38,062 | 0 | 0 | 0 | For |
| Northern Trust | 35,216 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 32,950 | 0 | 0 | 0 | For |
| Dimensional | 30,274 | 0 | 0 | 0 | For |
| Pacific Life | 27,935 | 0 | 0 | 0 | For |
| Brighthouse | 26,829 | 0 | 0 | 0 | For |
| State Street | 25,212 | 0 | 0 | 0 | For |
| John Hancock | 24,718 | 0 | 0 | 0 | For |
| AQR | 23,960 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,872 | 0 | 0 | 0 | For |
| Voya | 19,830 | 0 | 0 | 0 | For |
| ProShares | 18,485 | 0 | 0 | 0 | For |
Fund voting reports, all 40 managers: 9,853,955 for, 167,610 against, 18,119 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10,259,409 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 9,434,612 | 0 | 0 | 0 | For |
| Point72 | 4,712,829 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 4,325,772 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 3,487,903 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 3,227,792 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,461,987 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 2,228,886 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 2,196,553 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 2,141,587 | 0 | 0 | 0 | For |
| BlackRock | 1,893,152 | 23,016 | 0 | 0 | For |
| Woodline Partners LP | 1,622,098 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,604,174 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 1,411,963 | 0 | 0 | 0 | For |
| State Street | 1,379,721 | 662 | 0 | 0 | For |
| BRAIDWELL LP | 1,289,660 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 985,864 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 893,000 | 0 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 740,885 | 0 | 0 | 0 | For |
| Northern Trust | 472,871 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 368,600 | 0 | 0 | 0 | For |
| Nuveen | 273,620 | 0 | 0 | 0 | For |
| SEI | 250,287 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 232,945 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 227,641 | 0 | 0 | 0 | For |
Institutional-manager reports, all 109 managers: 60,300,362 for, 546,341 against, 23,528 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 37,159 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 39 managers: 37,159 for, 18,119 abstained, 9,926,711 1 year, 39,699 3 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0 | 0 | 0 | 0 | -- |
| NEA Management Company, LLC | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Rubric Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Vivo Capital, LLC | 0 | 0 | 0 | 0 | -- |
| VIKING GLOBAL INVESTORS LP | 0 | 0 | 0 | 0 | -- |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| Octagon Capital Advisors LP | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| BRAIDWELL LP | 0 | 0 | 0 | 0 | -- |
| Affinity Asset Advisors, LLC | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| Opaleye Management Inc. | 795,000 | 0 | 0 | 0 | For |
| Ally Bridge Group (NY) LLC | 740,885 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| STATE OF WISCONSIN INVESTMENT BOARD | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 107 managers: 1,563,108 for, 848 against, 59,861,668 1 year, 37,183 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
Trevi Therapeutics, Inc.’s own tally for this item (“2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025”): 88,898,357 for, 56,824 against — passed, per its Form 8-K filed June 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025 was ratified.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 40 asset managers below reported 10,021,565 for, 18,119 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,014,667 | 0 | 0 | 0 | For |
| BlackRock | 2,890,954 | 0 | 0 | 0 | For |
| Fidelity | 1,495,735 | 0 | 0 | 0 | For |
| TIAA | 265,706 | 0 | 0 | 0 | For |
| Charles Schwab | 211,923 | 0 | 0 | 0 | For |
| Equitable | 152,415 | 0 | 0 | 0 | For |
| SEI | 145,268 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,779 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,659 | 0 | 0 | 0 | For |
| American Century | 76,904 | 0 | 0 | 0 | For |
| Global X | 43,327 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 42,881 | 0 | 0 | 0 | For |
| Invesco | 41,493 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 38,062 | 0 | 0 | 0 | For |
| Northern Trust | 35,216 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 32,950 | 0 | 0 | 0 | For |
| Dimensional | 30,274 | 0 | 0 | 0 | For |
| Pacific Life | 27,935 | 0 | 0 | 0 | For |
| Brighthouse | 26,829 | 0 | 0 | 0 | For |
| State Street | 25,212 | 0 | 0 | 0 | For |
| John Hancock | 24,718 | 0 | 0 | 0 | For |
| AQR | 23,960 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,872 | 0 | 0 | 0 | For |
| Voya | 19,830 | 0 | 0 | 0 | For |
| ProShares | 18,485 | 0 | 0 | 0 | For |
Showing the 25 largest of 40 asset managers. All 40 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 99,892,915 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.02% |
| 2 | BlackRock | 2.89% |
| 3 | Fidelity | 1.50% |
| 4 | TIAA | 0.27% |
| 5 | Charles Schwab | 0.21% |
| 6 | Equitable | 0.15% |
| 7 | SEI | 0.15% |
| 8 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 9 | Lincoln Financial | 0.09% |
| 10 | American Century | 0.08% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 10.27% |
| 2 | NEA Management Company, LLC | 9.44% |
| 3 | Point72 | 4.72% |
| 4 | Rubric Capital Management LP | 4.33% |
| 5 | Vivo Capital, LLC | 3.49% |
| 6 | VIKING GLOBAL INVESTORS LP | 3.23% |
| 7 | Siren, L.L.C. | 2.46% |
| 8 | MPM BioImpact LLC | 2.23% |
| 9 | MARSHALL WACE, LLP | 2.20% |
| 10 | Octagon Capital Advisors LP | 2.14% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| New Enterprise Associates 16, L.P. | 15,074,080 | 15.09% | Schedule 13D, filed May 7, 2026 |
| James N. Topper | 10,259,409 | 10.27% | Schedule 13G, filed May 15, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 8,508,021 | 8.52% | Schedule 13G, filed November 14, 2025 |
| FMR LLC | 8,038,061 | 8.05% | Schedule 13G, filed May 6, 2026 |
| BlackRock | 5,312,542 | 5.32% | Form 13F, quarter ended March 31, 2025 |
| VIKING GLOBAL INVESTORS LP | 5,128,875 | 5.13% | Schedule 13G, filed November 14, 2025 |
| Vanguard Group | 3,838,032 | 3.84% | Form 13F, quarter ended March 31, 2025 |
| Point72 | 2,368,005 | 2.37% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 1,614,865 | 1.62% | Form 13F, quarter ended March 31, 2025 |
| State Street | 1,424,506 | 1.43% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 99,892,915 shares outstanding, as reported by Trevi Therapeutics, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Trevi Therapeutics, Inc.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 133 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 957 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — Trevi Therapeutics, Inc.'s filing reports the proposal as approved, with 99.1% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Trevi Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Trevi Therapeutics, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Trevi Therapeutics, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Trevi Therapeutics (TRVI) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/trevi-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.